(AOF) – Medesis Pharma announces that it has “successfully reached a key milestone in its phase 2 clinical study for the treatment of Alzheimer’s disease”. The biotech developing drug candidates based on its proprietary technology for administering active ingredients in nanomicelles orally, Aonys, is also making public the securing of a new cash contribution of 400,000 euros. It will be finalized at the end of February and will be done on the same principles as in December 2023.
She also plans a scientific publication on treatment with NanoLithium, her participation in the Biomed Forum on January 30, 2024.
Medesis Pharma requested and obtained the opening, on September 29, 2023, of a safeguard procedure with the Montpellier Commercial Court. This can last up to twelve months and leads to the temporary suspension of its financial and tax obligations.
The resources from this next capital increase allow Medesis Pharma to extend its cash flow horizon during the month of February 2024.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
